Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2025-12-31
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spontaneous coronary artery dissection (SCAD)
Subject has a history of spontaneous coronary artery dissection (SCAD)
Stress Echocardiography with Contrast
Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
Healthy Subjects
Subjects are healthy with no significant medical history
Stress Echocardiography with Contrast
Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stress Echocardiography with Contrast
Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a history of spontaneous coronary artery dissection (SCAD) OR patient is healthy with no significant medical history
Exclusion Criteria
* Allergic or have a history of adverse reaction to dobutamine, the Definity® ultrasound enhancing agent, or atropine.
* Has a known or suspected hypersensitivity to perflutren and therefore cannot be given Definity®.
* Pregnant.
* Unable to interrupt breastfeeding.
* Within 3 months of a heart attack.
* Severe aortic stenosis.
* Severe, uncontrolled hypertension (\>200/110 mmHg at baseline).
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marysia Tweet
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marysia Tweet, M.D., M.S.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pamela Engrav
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-002318
Identifier Type: -
Identifier Source: org_study_id